每经AI快讯，漱玉平民（SZ 301017，收盘价：13.98元）11月28日晚间发布公告称，公司于近日收到公 司持股5%以上股东秦光霞女士的通知，获悉其所持有公司的部分股份办理了质押业务，此次质押2020 万股。 截至发稿，漱玉平民市值为57亿元。 2025年1至6月份，漱玉平民的营业收入构成为：零售占比87.34%，批发收入占比9.4%，促销和陈列与 咨询服务收入占比2.49%，其他业务占比0.77%。 （记者 贾运可） 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 ...

Core Insights - The report provides a summary of recommended stocks across various industries for December 2025, highlighting investment logic and potential growth opportunities for each company [2]. Industry Summaries Construction - Shenghui Integrated (603163.SH) is a Taiwanese cleanroom engineering service provider and a core engineering supplier for Google's TPU, poised to benefit from TSMC's expansion in the U.S. with potential orders from TSMC Arizona and multiple North American data centers [2]. Banking - China Merchants Bank (600036.SH) is expected to attract investors due to its stable operations and a projected dividend yield of 4.62% for the 2024 annual report, with increased demand for low-volatility stocks as market fluctuations rise [2]. Electronics - Aojie Technology (688220.SH) is positioned to benefit from the AI trend, with its unique 2-5G full-standard cellular communication capabilities and strong ASIC customization experience, which are expected to drive growth in wearable technology and other applications [2]. Power Equipment and New Energy - Delijia (603092.SH) maintains a leading market share in wind power main gearboxes, with a projected global market size of $11.563 billion by 2030 and a compound annual growth rate of 5.10% from 2024 to 2030, indicating stable growth prospects [2]. Basic Chemicals - Yaqi International (000893) is set to increase its potash fertilizer production capacity significantly, benefiting from a rising global potash market [2]. Agriculture, Forestry, Animal Husbandry, and Fishery - Youran Dairy (9858.HK), a leading global dairy farming company, is expected to benefit from rising milk prices and beef prices, leading to improved performance [2]. Internet - Alibaba (9988.HK) is experiencing accelerated growth in cloud revenue, with a 34% year-on-year increase in FY26Q2, and is expected to continue improving profitability through enhanced user engagement and AI integration [2]. Pharmaceuticals - Yifeng Pharmacy (603939.SH) is anticipated to see profit improvements due to ongoing optimization of its store structure and a clear plan for non-pharmaceutical profit growth [2]. Home Appliances - Midea Group (000333.SZ) is focusing on dual-driven strategies in domestic and international markets, with strong cash flow and a favorable dividend yield, despite facing some pressure in Q4 [2]. Non-Bank Financials - Ping An Insurance (601318.SH) is increasing investments in high-quality long-term assets, with potential for valuation improvement as market conditions shift [2].

Core Insights - The report provides a summary of recommended stocks across various industries for December 2025, highlighting investment logic and potential growth opportunities for each company [2]. Industry Summaries Construction - Shenghui Integrated (603163.SH) is a Taiwanese cleanroom engineering service provider and a core engineering supplier for Google's TPU, poised to benefit from TSMC's expansion in the U.S. with potential orders from TSMC Arizona and multiple North American data centers [2]. Banking - China Merchants Bank (600036.SH) is expected to attract investors due to its stable operations and a projected dividend yield of 4.62% for the 2024 annual report, with increased demand for low-volatility stocks as market fluctuations rise [2]. Electronics - Aojie Technology (688220.SH) is positioned to benefit from the AI trend, with its unique 2-5G full-standard cellular communication capabilities and strong ASIC customization experience, which is expected to drive growth in wearable technology [2]. Power Equipment and New Energy - Delijia (603092.SH) maintains a leading market share in wind power main gearboxes, with a projected global market size of $11.563 billion by 2030 and a compound annual growth rate of 5.10% from 2024 to 2030 [2]. Basic Chemicals - Yaqi International (000893) is set to increase its potash fertilizer production capacity significantly, benefiting from a rising global potash market [2]. Agriculture, Forestry, Animal Husbandry, and Fishery - Youran Dairy (9858.HK), a leading global dairy farming company, is expected to benefit from rising milk prices and beef price increases, leading to improved performance [2]. Internet - Alibaba (9988.HK) is experiencing accelerated growth in cloud revenue, with a 34% year-on-year increase in FY26Q2, and is expected to continue improving profitability [2]. Pharmaceuticals - Yifeng Pharmacy (603939.SH) is anticipated to see profit improvements due to ongoing optimization of its store structure and a clear planning rhythm for non-pharmaceutical profit increments [2]. Home Appliances - Midea Group (000333.SZ) is advancing its dual-driven strategy, focusing on both B2B and B2C markets, with strong cash flow and a favorable dividend yield, making it an attractive investment [2]. Non-Banking Financials - Ping An Insurance (601318.SH) is increasing investments in high-quality long-term assets, with potential for valuation improvement as market conditions shift [2].

Overall Viewpoint - The core viewpoint of the report emphasizes that demand is the source of strength and innovation is the light that breaks the deadlock in the pharmaceutical industry. The continuous demand for pharmaceuticals and the increasing unmet needs drive pharmaceutical companies to invest in research and development, leading to explosive revenue and stock price growth [5][7][13]. Innovation Drugs - China has become a significant participant in global innovative drug research and development, with a high-quality growth rate of therapies in development far exceeding the global average. The domestic innovative drug sector is entering a revenue era driven by innovation, creating a positive dynamic between traditional pharmaceutical companies and emerging players [5][7][27]. - The number of domestic new drug overseas authorizations has surpassed $10 billion since 2021, indicating a sustained increase in overseas authorization activity, which continues to propel China's innovative drugs into the global market [5][7][27]. Pharmaceutical Industry - The report indicates that the innovative layout in the pharmaceutical industry is beginning to yield results, with performance expected to accelerate. Many companies are transitioning to a growth phase driven by innovation, suggesting that the current period is just the beginning of a more significant performance acceleration [5][7][27]. CXO Sector - Starting in the second half of 2024, global pharmaceutical research and development demand is expected to gradually recover, with strong demand for new molecular types such as peptides and ADCs driving growth in the CDMO segment. The value of leading CRO companies is anticipated to further highlight as the difficulty and barriers in drug development increase [5][7][27]. API Sector - The core business of API companies is primarily focused on non-U.S. exports (to Europe and India), with current demand remaining strong. Leading companies are achieving positive results in expanding into CDMO businesses, and many have integrated local market formulation businesses, which are expected to benefit from the easing of centralized procurement policies [5][7][27]. Medical Devices - The high-value consumables sector is experiencing a reduction in procurement pressure, with performance expected to return to a high growth trajectory. The report highlights that the bidding for medical devices is recovering, indicating an upcoming turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [5][7][27]. Traditional Chinese Medicine - The report expresses optimism for the recovery of the traditional Chinese medicine sector in 2026, with upward factors outweighing downward ones. The expected recovery sequence for sub-sectors includes hospital-based traditional Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer traditional Chinese medicine [5][7][27]. Medical Services - The report anticipates that with the introduction of several positive macro policies, consumer expectations are likely to recover. If favorable local fiscal policies are implemented, the bad debts and payment cycles for private hospitals will also see substantial relief, alleviating market concerns [5][7][27]. Pharmaceutical Retail - The pharmaceutical retail sector has faced continuous pressure since Q3 2024, primarily due to declining demand for four categories of drugs, consumption downgrading, intensified competition, and fluctuations in medical insurance policies. However, as high baselines are gradually digested, the revenue growth of leading chains is expected to stabilize and improve [5][7][27]. Blood Products - Despite short-term performance pressures, the essential nature of blood products indicates that supply and demand are expected to rebalance. The diversity of products among companies is rapidly increasing, with high-value new products like immunoglobulin expected to drive industry growth [5][7][27]. Life Sciences Services - The life sciences services sector is experiencing a demand recovery, coupled with deepening domestic substitution and ongoing overseas expansion, leading to a positive quarterly revenue growth starting from Q4 2024. The net profit margin of the sector has been gradually improving, indicating sustained profitability [5][7][27].

Core Insights - The pharmaceutical industry is expected to reach new highs globally due to persistent human demand and unmet needs, alongside increased R&D investments by pharmaceutical companies [1] - Continuous innovation and successful outcomes are essential for pharmaceutical companies to achieve explosive revenue and stock price growth [1] Group 1: Innovative Drugs - China has seen a high-quality growth in the number of innovative therapies in development, significantly outpacing the global average, establishing itself as a key player in global innovative drug R&D [2] - Since 2021, the total overseas licensing amount for domestic new drugs has exceeded $10 billion, with ongoing growth in overseas licensing driving China's share in the global market [2] - The industry is entering an "innovation-driven" revenue era, fostering a positive dynamic between traditional pharmaceutical companies and emerging players [2] Group 2: Pharmaceutical Industry - The industry is experiencing accelerated growth as companies reap the benefits of years of R&D, with many transitioning to innovation-driven growth phases [2] - The current period is seen as just the beginning of a harvest phase, with future performance expected to further accelerate [2] Group 3: CXO Sector - Starting in the second half of 2024, global pharmaceutical R&D demand is anticipated to recover, with leading CXO companies seeing a gradual increase in orders and revenue [2] - There is strong demand for new molecular types such as peptides, small nucleic acids, and ADCs, which is driving high prosperity in the CDMO segment [2] - As drug development becomes more challenging, the value of leading CRO companies is expected to become more pronounced [2] Group 4: API Sector - API companies primarily focus on non-U.S. exports (Europe/India), with strong current demand [3] - Leading companies are achieving positive results in expanding into CDMO businesses, leveraging their robust EHS and GMP systems [3] - Many companies are also integrating local market formulation businesses, poised to benefit from easing centralized procurement pressures [3] Group 5: Medical Devices - The high-value consumables sector is expected to return to a high growth trajectory as procurement pressures ease, with innovation driving ongoing development and value reassessment [3] - The medical equipment bidding process is recovering, indicating a turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [3] - The IVD industry is under pressure, but policy disruptions are gradually clearing, allowing leading domestic companies to increase market share [3] Group 6: Traditional Chinese Medicine - The traditional Chinese medicine sector is expected to recover significantly, driven by improved chip structure, favorable policies, and inventory reduction [3] - The anticipated recovery sequence for sub-sectors includes hospital-based Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer Chinese medicine [3] Group 7: Medical Services - Positive macro policies are expected to restore consumer confidence, alleviating concerns about private hospitals' bad debts and payment cycles [4] Group 8: Pharmaceutical Retail - The pharmaceutical retail sector has faced ongoing pressure since Q3 2024 due to declining demand for four categories of drugs, consumer downgrading, and intensified competition [4] - Drugstores are responding by closing locations and enhancing efficiency, with expectations for recovery as high baseline effects are gradually digested [4] Group 9: Blood Products - Despite short-term performance pressures, the essential nature of blood products suggests a return to supply-demand balance [4] - The variety of products is increasing rapidly, with high-value new products expected to drive industry growth [4] Group 10: Life Sciences Services - The sector is seeing a recovery in demand, supported by deepening domestic substitution and ongoing international expansion, with quarterly revenue expected to turn positive from Q4 2024 [4] - The net profit margin for the sector has been improving, indicating sustained profitability growth [4]

Group 1 - The company, Yixin Tang (002727), enhances efficiency in its supply chain through various methods including information connectivity, data analysis, mobile applications, modern warehousing construction, and logistics monitoring [1]

Group 1 - The company, Yixin Tang, stated on November 26 that it will introduce new technologies in its management processes to enhance operational efficiency [2]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

来源：新浪证券-红岸工作室 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 机构持仓方面，截止2025年9月30日，华人健康十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股232.03万股，相比上期增加133.57万股。 11月21日，华人健康跌5.82%，成交额1.97亿元。两融数据显示，当日华人健康获融资买入额1291.82万 元，融资偿还3237.85万元，融资净买入-1946.03万元。截至11月21日，华人健康融资融券余额合计1.42 亿元。 融资方面，华人健康当日融资买入1291.82万元。当前融资余额1.42亿元，占流通市值的 ...

11月21日，漱玉平民跌2.84%，成交额2.28亿元。两融数据显示，当日漱玉平民获融资买入额1559.09万 元，融资偿还1700.37万元，融资净买入-141.28万元。截至11月21日，漱玉平民融资融券余额合计 8035.09万元。 截至9月30日，漱玉平民股东户数1.31万，较上期减少7.43%；人均流通股18643股，较上期增加8.02%。 2025年1月-9月，漱玉平民实现营业收入74.46亿元，同比增长5.19%；归母净利润1.09亿元，同比增长 927.37%。 分红方面，漱玉平民A股上市后累计派现1.41亿元。近三年，累计派现6673.17万元。 机构持仓方面，截止2025年9月30日，漱玉平民十大流通股东中，香港中央结算有限公司位居第九大流 通股东，持股78.60万股，相比上期减少47.65万股。 责任编辑：小浪快报 融资方面，漱玉平民当日融资买入1559.09万元。当前融资余额8035.09万元，占流通市值的1.52%，融 资余额超过近一年90%分位水平，处于高位。 融券方面，漱玉平民11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0. ...